GLAS Glass House Brands Inc. Annual reports only
Medicinal Chemicals & Botanical Products · NYSE · SEC CIK 1848731 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-9.4%
TTM net income YoY-5,814.6%
TTM EPS YoY-161.9%
Revenue 3-yr CAGR28.9%
Net income 3-yr CAGR—
Margins
Gross margin42.3%
Operating margin-9.1%
Net margin-16.3%
FCF margin-8.6%
EBITDA margin-0.8%
Returns
ROE-31.2%
ROA-9.4%
ROIC (approx.)-10.2%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets45.2%
Debt / equity0.93x
Current ratio1.78x
Interest coverage-2.34x
Cash quality & payout
Operating cash flow / net income-0.39x
Accruals ratio-13.1%
Payout ratio—
Capex / revenue14.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $181.98M | $200.90M |
| Cost of revenue | $105.02M | $103.50M |
| Gross profit | $76.96M | $97.39M |
| SG&A expense | $64.10M | $60.13M |
| Operating income | -$16.53M | $5.74M |
| Interest expense | $7.06M | $9.18M |
| Pretax income | -$17.02M | $11.22M |
| Income tax | $11.93M | $10.50M |
| Net income | -$29.66M | $519,000 |
| EBITDA | -$1.53M | $20.04M |
| EPS (basic) | -0.55 | -0.21 |
| EPS (diluted) | -0.55 | -0.21 |
| Weighted avg. shares (diluted) | 81.94M | 75.23M |
| Balance sheet | ||
| Cash & equivalents | $23.35M | $36.92M |
| Receivables | $4.42M | $5.22M |
| Inventory | $26.23M | $14.25M |
| Current assets | $67.75M | $66.10M |
| PP&E, net | $228.76M | $212.25M |
| Goodwill | — | $0 |
| Intangibles | $11.58M | $14.20M |
| Total assets | $318.56M | $310.50M |
| Current liabilities | $37.96M | $66.48M |
| Short-term debt | $37,000 | $7.64M |
| Long-term debt | $68.63M | $50.55M |
| Total debt | $68.67M | $58.20M |
| Total liabilities | $143.96M | $146.45M |
| Shareholders' equity | $73.94M | $116.24M |
| Net debt | $45.32M | $21.27M |
| Cash flow statement | ||
| Operating cash flow | $11.45M | $28.39M |
| Capital expenditure | $27.18M | $10.29M |
| Free cash flow | -$15.73M | $18.10M |
| Investing cash flow | -$27.74M | -$10.29M |
| Financing cash flow | $2.72M | -$13.70M |
| Depreciation & amortization | $15.00M | $14.30M |
| Stock-based compensation | $13.40M | $13.10M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.